Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
January 13, 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
July 21, 2025
Energy Current
DOE Announces Pilot Program to Build Advanced U.S. Nuclear Fuel Supply Lines: What You Need to Know Now
Introduction Coming on the heels of its June 2025 announcement establishing a pilot program for reactor construction and operation in…
July 21, 2025
Labor & Employment Law Perspectives
Considering a Reduction in Force? Some Preliminary Considerations
Employers sometimes find it necessary to make the difficult decision to undergo a reduction-in-force (RIF), resulting in employee layoffs…
November 13, 2025
Events
Shaping Tomorrow: Industry Trends Through Legal, Financial, and Economic Lenses
On September 13, Foley senior counsel Charles Gass will speak on the panel “Shaping Tomorrow: Industry Trends Through Legal, Financial, and Economic” during the Colorado Ambulatory Surgery Center Association’s (CASCA) Annual Conference & Trade Show. Gass is also CASCA’s general counsel.